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HISTORY
In 1955, Festenstein et al. (1955) , the scientists in Morton's Laboratory in Liverpool (England) isolated an unsaponifiable lipid with a striking ultraviolet absorption at 272 nm from the intestinal mucosa of horses. Because the new substance was identified as a quinone and was found to be widely distributed in animal tissues, Morton named it ubiquinone (ubiquitous quinone -everywhere present quinone). Two years later in David Green's Laboratory at the University of Wisconsin (USA), Crane et al. (1957) observed a novel quinone in the lipid extracts of mitochondria and named it coenzyme Q because of its participation in the electron transport chain.
One year later, the chemical structure of coenzyme Q 10 (CoQ 10 ) was reported by Wolf (Olson 2001) , under Dr. Folkers at Merck Laboratories. Later on the Folkers' laboratory became a centre for the purification, structural determination and synthesis of a large number of nourishing factors, besides CoQ 10 , for example, also vitamin B 6 , pantothenic acid, biotin, vitamin B 12 , and mevalonic acid (Olson 2001) .
In 1963, Professor Yamamura from Japan was the first to use coenzyme Q 7 in the treatment of a human disease: congestive heart failure. Mellors and Tappel (1966a, b) showed that reduced CoQ 6 was an effective antioxidant. In 1972 Littarru along with Folkers documented a deficiency of CoQ 10 in human heart disease (Littarru et al. 1972) . Ernster (1977) from Sweden enlarged upon the importance of CoQ 10 as an antioxidant and free radical scavenger. Peter D. Mitchell, a British biochemist, received the Nobel Prize in 1978 for his contribution to the understanding of the biological energy transfer through the formulation of the chemiosmotic theory, which includes the vital protonmotive role of CoQ 10 in the energy transfer systems (Mitchell 1961 (Mitchell , 1966 .
In the early 1980's, there was a considerable acceleration in the number and size of clinical trials. Folkers received the Priestly Medal from the American Chemical Society in 1986 and the National Medal of Science from President Bush in 1990 for his work with CoQ 10 and other nutrients (Olson 2001) . CoQ 10 has become a science subject of many researches.
Chemical and physical properties of CoQ 10
Ubiquinone, chemically 2,3-dimethoxy-5-methyl-6-polyisoprene parabenzoquinone (Figure 1 ), is in its natural form an orange lipophile powder, without odour and taste. Because CoQ 10 has 10 isoprenoid units -its name is coenzyme Q 10 . Molecular weight of CoQ 10 is 863.34 g/mol. CoQ 10 is not very stable and deteriorates at temperatures of about 46°C (US Patent 2005) . It is a biologically active quinone; it comprises a benzoquinone ring with an isoprenoid side chain, related in structure to vitamin K and vitamin E.
CoQ 10 is the most prevalent form in humans and most mammals. It has been found also in other animals, microorganisms, and plants. CoQ 9 is the primary form found in rats and mice (Ramasarma 1985) . Coenzymes Q 6 , Q 7 , and Q 8 (6, 7 or 8 isoprenoid units, respectively), are found in yeasts and bacteria (Overvad et al. 1999) .
The main chemical characteristic of CoQ 10 , responsible for its various functions, is its existence in three alternate redox states (Battino et al. 1990; James et al. 2004 ):
(1) The fully oxidised ubiquinone form which, upon two sequential additions of hydrogen atoms, converts first into a partially reduced; (2) Semiquinone -free radical form; (3) The fully reduced ubiquinol form (Figure 2) .
CoQ 10 can exist in either the cis or the trans forms. Only the trans form is found in nature. However, both forms can be produced in a mixture by means of biofermentation or a chemical process (US Patent 2003) .
Biochemistry in the human organism
In cells, CoQ 10 is located in the middle of the phospholipids bilayer of various membranes; however, the relative amount varies in different organelles. CoQ 10 is found in the membranes of (Crane et al. 1984) . It is found in relatively higher concentrations in cells with high energy requirements, such as those of the heart, liver, muscles and pancreas. The biosynthesis of CoQ 10 from the amino acid tyrosine is a 17-step process (Figure 3 ) requiring at least eight vitamins (riboflavin, pyridoxine, niacinamide, ascorbic acid, cobalamin, folic acid, tocopherol, and pantothenic acid) and several trace elements (Hojerová 2000; Crane 2001 ).
Because of this biosynthesis complexity, defects in some human enzymes or regulatory proteins may cause CoQ 10 deficiency in infantile and adult organisms (Quinzii et al. 2007) .
CoQ 10 is the cofactor for at least three mitochondrial enzymes (complexes I, II and III) as well as enzymes in other parts of the cell James et al. 2004) .
Mitochondrial enzymes of the oxidative phosphorylation pathway are essential for the production of the high-energy phosphate, adenosine triphosphate (ATP), upon which all cellular functions depend. The electron and proton transfer functions of the quinone ring are of fundamental importance to all life forms; ubiquinone in the mitochondria of animals, plastoquinone in the chloroplasts of plants, and menaquinone in bacteria (Littarru 1994; Crane 2001) .
Antioxidant activity
CoQ 10 is only endogenously synthesised lipid soluble antioxidant, present in all membranes and surpassing both in the amount and efficiency other antioxidants. The protective effect is extended to lipids proteins and DNA mainly because of its close localisation to the oxidative events and the effective regeneration by continuous reduction at all locations (Bentinger et al. 2007) .
CoQ 10 in its reduced form as a hydroquinone (ubiquinol) (Figure 2 ) is a potent lipophilic antioxidant that has a great importance as a free radical scavenger. CoQ 10 protects the stability of the cell membranes, protects DNA from free radical induced oxidative damage, and is capable of recycling and regenerating other antioxidants, such as tocopherol and ascorbate (Crane 2001) . Other important functions of CoQ 10 as e.g. cell signalling and gene expression have also been described (Bhagavan & Chopra 2006) . cient in coenzyme Q synthesis shows more lipid peroxide formation than normal yeast (Poon et al. 1997) . Another direct demonstration of the elimination of free radicals is shown by coenzyme Q treatment of skin in elderly subjects. Luminescence is eliminated from free radicals when a skin cream containing coenzyme Q is applied (Hoppe et al. 1999) .
With tocopherol, ubiquinol acts as an antioxidant to stem lipid peroxidation in the inner mitochondrial membrane (Kagan et al. 1990; ForsmarkAndree et al. 1995; Lass & Sohal 1998; James et al. 2004) . Ubiquinol can rescue tocopheryl radicals produced by the reactions with lipid or oxygen radicals by a direct reduction back to tocopherol (Arroyo et al. 2000) . Without coenzyme Q in the membrane, regeneration of tocopherol is very slow. The regeneration of tocopherol can also be observed in low density lipoprotein where a small amount of coenzyme Q protects a larger amount of tocopherol. This function is presumably favoured by the high percentage of quinol present in the blood (Thomas et al. 1999; Schneider & Elstner 2000; Crane 2001 ).
Levels of CoQ 10 in the human organism
The concentrations of CoQ 10 in the human organism depend on age, sex, race, and health of the individual. In a healthy young organism is a sufficient amount of CoQ 10 . There are some studies about plasma or serum CoQ 10 concentrations, which are usually employed for the assessment of CoQ 10 status in humans, primarily because of the ease of the sample collection. There are several excellent methods based on HPLC for the analysis of CoQ 10 in plasma or serum (Lang & Parcker 1987; Grossi et al. 1992; Gvozdjáková et al. 2000; Tang et al. 2001) .
From 1996 to 2000, Gvozdjáková et al. (2000) measured CoQ 10 levels in 3000 blood samples of the Slovak population. Tested were: healthy volunteers, stressed managers, two Slovak astronauts, who were getting ready for the start to Cosmos, 30 Slovak fighter pilots, people working with ionising radiation, patients with diabetes, patients with osteoporosis, patients with chronic heart disease, patients before and after heart transplantation, patients with nephropathy, and patients with myopathy. The authors reported that the blood values of CoQ 10 in healthy volunteers ranged from 0.40 to 0.45 μg/ml (0.46 to 0.52 μmol/l). In the other blood samples of the people or patients groups, CoQ 10 deficit was proved in comparison with healthy volunteers (Figure 4) . Kaikkonen et al. (2002) reported plasma CoQ 10 values ranging from 0.40 to 1.72 μmol/l in males and 0.43 to 1.47 μmol/l in females in Finnish population. Similar data are available for the US population. Miles et al. (2003) reported a range from 0.50 to 1.91 μmol/l that included black and white person of both sexes. Plasma CoQ 10 concentration ranges were higher in white males than in white females and this is consistent with the findings of Kaikkonen et al. (2002) . In their study, black people had higher plasma CoQ 10 values than the white people although their reference interval fitted within the reference interval for the white. The reasons for this
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A -healthy people B -stressed people (managers) C -2 Slovak astronauts made ready for start to Cosmos D -30 Slovak fighter pilots E -people working with ionising radiation F -patients with insulin dependent diabetes mellitus G -patients with non insulin dependent diabetes mellitus patients H -patients with nephropathy I -patients with myopathy J -patients with osteoporosis K -patients with chronic heart disease L -patients with cardiomyopathy of unknown ethiology M -patients after heart transplantation difference are not clear. By Hughes et al. (2002) , plasma concentrations of both the total and reduced CoQ 10 were found to be significantly lower in Asian Indian males than those in Chinese males in the Singaporean population which was presumed to be one reason for the higher risk of coronary artery disease in Asian Indians.
The distribution and contents of ubiquinones in foods
Intracellular synthesis in human body is the major but not the only source of CoQ 10 . The rest can be synthesised in liver from the nourishment. CoQ 10 is found in small amounts in a wide variety of foods from animal sources. Mattila and Kumpulainen (2001) reported that meat and fish (fresh sardines and mackerels) were the richest sources of CoQ 10 . Especially, reindeer steak as well as beef and pork heart had very high contents of CoQ 10 (113.3-157.9 µg/g). The contents in fish and other meat samples varied in ranges from 14.0 to 39.2 µg/g). Similar results were published by Weber et al. (1997) .
There are plenty of vegetable CoQ sources -plastoquinone Q 10 and Q 9 , the richest being spinach, broccoli, peanuts, wheat germ and whole grains, although the amounts are significantly smaller than those found in meat. Kamei et al. (1986) determined 92.3 µg/g in corn oil and 73.4 µg/g CoQ 10 in rapeseed oils. . By Mattila and Kumpulainen (2001) , rapeseed oils contain 63.5 µg/g CoQ 10 (Table 1) . Vegetables, fruits, berries, and dairy products contain relatively low levels of CoQ 10 . In cereals, the contents of this compound were below the detection limit (Table 1) . Gvozdjáková et al. (1996 Gvozdjáková et al. ( , 2002 measured CoQ 10 levels (as plastoquinone Q 10 -PQ 10 ) and CoQ 9 levels (as plastoquinone Q 9 -PQ 9 ) in several kinds of grape. The authors reported that different concentrations of the antioxidant compounds were found in their berries, skins, and pulps. Several times higher concentration of PQ 10 was estimated in the skin and berry of St. Laurent, and of PQ 9 in the berry, skin, and pulp of Riesling × Sylvaner as compared to other grapes (Table 3) . Gvozdjáková et al. (2002) also found that "wine ageing" has an effect on PQ 10 concentrations almost in all varieties of 14-week aged wine in comparison with 4-week aged wine (young wine) (Table 4) .
CoQ 10 is an interesting theme for genetic research, too. For example: in natural rice (Takahashi et al. 2006) and in cereals (Mattila & Takahashi et al. (2006) modified the lenght of the side chain of CoQ from 9 to 10 units by expressing DdsA (decaprenyl diphosphate synthetase) to produce CoQ 10 in rice. They showed that in the leaves and seeds of transgenic rice CoQ 10 is predominantly produced.
Nutritional supplement
At the present time, CoQ 10 is very popular as a freely available dietary supplement. But there is only little relevant research into its appropriate dose and bioavailability. The recommended daily intake for CoQ 10 has not yet been established by legislation. Generally, the suitable dose of CoQ 10 for adult people depends an age, sex, race, and psychical and physical conditions. By Overvard et al. (1999) , a dose of CoQ 10 for a nutritional supplement ranging between 30 to 150 mg/day was suggested. Higher doses of CoQ 10 were recommended therapeutically only.
The dietary supplements of CoQ 10 are offered in different formulations: oil-based capsules (soybean oil or other vegetable oil), capsules on hydrophilic-gel (solubilised form), powder-filled capsules, and tablets, for example effervescent. One dose of these contains usually 15, 30, or 60 mg CoQ 10 . These are often combined in the dietary supplements with tocopherol, resveratrol, folic acid, l-carnitine, yeasts, magnesium, selenium or other mineral and trace elements. Joshi et al. (2003) found that orally-administered CoQ 10 was more rapidly delivered to the blood when formulated as an effervescent tablet or as a fast-melting tablet than in other forms. Toxicity (Joshi et al. 2003) . Because of its hydrophobicity and large molecular weight, the absorption of dietary CoQ 10 is slow and limited. Gvozdjáková et al. (1999 Gvozdjáková et al. ( , 2002 Gvozdjáková et al. ( , 2004 Gvozdjáková et al. ( , 2005 following their research reported high bioavailability of CoQ 10 in capsules in its hydrosoluble form. According to US Patent (2003) good absorption of CoQ 10 is in capsules in its oil-water emulsion form. As CoQ 10 is not toxic (no side effects were reported), no medical conditions known preclude it use. In the case of dietary supplements, solubilised CoQ 10 formulations show enhanced bioavailability (Bhagavan & Chopra 2006) . Most suppliers recommend to take CoQ 10 may be taken with fatty foods.
Topical supplement
CoQ 10 along with vitamin E, vitamin C and superoxiddismutase plays a key role in the skin protective network. In the skin, the reduced form of CoQ 10 (ubiquinol) acts as an antioxidant with 10-fold higher levels in the epidermis than in the dermis (Shindo et al. 1994) . By Hojerová (1999) , ageing, poor eating habits, stress, and infection -they all affect the ability to provide adequate amounts of CoQ 10 in the skin. After the age of 35, the organism begins to lose its ability to synthesise CoQ 10 from food and its deficiency develops (Hojerová 2000) . Hoppe et al. (1999) estimated CoQ 10 increases in the skin of the human skin from childhood to maturity and then decreases with age and under irradiation with UVA rays. Therefore, oral supplementation with CoQ 10 may be very helpful for the skin health.
During the last decade, CoQ 10 has reached a leading position in the topical products, too. There are numerous topical formulations containing CoQ 10 , claiming to possess of antioxidant effects, skin repair and regeneration abilities as well as anti-wrinkling and anti-ageing capability (Hojerová et al. 2006) . Vinson and Anamandla (2006) demonstrated in vivo antioxidative effects in the skin of young and middle-aged subjects of two forms of CoQ 10 after a single dose and after a long-term supplementation.
Although many scientific articles on the medical benefits of CoQ 10 have been presented, little has been published on pharmacokinetics during its topical administration. Koprda et al. (2005) monitored CoQ 10 penetration across snakes skins. Since CoQ 10 is a large thermolabile and highly lipophilic molecule, the topical bioavailability is not very great. The carrier system is one of the important factors to determine pharmacokinetic of the skin penetration. The latest technical developments by Zulli et al. (2006) repeal that the encapsulation of CoQ 10 in liposomes or nanoemulsions results in a significantly enhanced bioavailability.
CoQ 10 and diseases
Normal blood and tissue levels of CoQ 10 have been established by numerous investigators. Significantly decreased levels of CoQ 10 have been noted in a wide variety of diseases in both animal and human studies. CoQ 10 deficiency may be caused by an insufficient dietary CoQ 10 intake, the impairment in CoQ 10 biosynthesis, excessive utilisation of CoQ 10 by the body, or any combination of the three. A decreased dietary intake is presumed in chronic malnutrition and cachexia (Littarru et al. 1991) .
Animal data show that CoQ 10 in large doses is taken up by all tissues including the heart and brain mitochondria. This fact has implications for therapeutic applications in human diseases, and evidence exists for its beneficial effects in cardiovascular and neurodegenerative diseases (Bhagavan & Chopra 2006) .
CoQ 10 and cardiovascular diseases. CoQ 10 is known to be highly concentrated in the heart muscle cells due to the high energy requirements of this cell type. For the past 14 years, the great bulk of clinical work with CoQ 10 has focused on heart disease. Specifically, congestive heart failure (from a wide variety of causes) has been strongly correlated with significantly low blood and tissue levels of CoQ 10 . The heart failure was found to correlate with the deficiency of CoQ 10 , which may well be the primary etiologic factor in some types of heart muscle dysfunction, while in others it may be a secondary phenomenon. The majority of clinical studies concerned the treatment of heart disease and they were remarkably consistent in their conclusions: the treatment with CoQ 10 significantly improved the heart muscle function while producing no adverse effects or drug interactions. There are many studies reporting positive results of oral administration of CoQ 10 as adjunctive therapy in the treatment of congestive heart failure (Kaikkonen et al. 2002; Gazdík et al. 2003) . In Japan and other countries, CoQ 10 is an approved treatment for several cardiovascular conditions. CoQ 10 may be useful in treating congestive heart failure as well as other heart conditions (Folkers et al. 1992) . Many studies have confirmed that CoQ 10 is safe. One of them, which evaluated the effects of CoQ 10 supplementation on 2500 patients diagnosed with congestive heart failure (50-150 mg of CoQ 10 daily for three months), reported that the patients showed a remarkable improvement in clinical signs and symptoms, without adverse side effects (Baggio et al. 1994 ). This study and many others conclude that CoQ 10 supplementation is safe and effective. By Gvozdjáková et al. (1999) , CoQ 10 whole blood levels in patients after heart transplantation were significantly lower in comparison with healthy persons. The level decreased significantly with incipient rejection in comparison with patients without signs of rejection.
CoQ 10 and hypertension. The results of several small, uncontrolled studies in humans suggest that CoQ 10 supplementation could be beneficial in the treatment of hypertension. More recently, two short-term placebo-controlled trials found that CoQ 10 supplementation resulted in moderate blood pressure decreases in hypertensive individuals. Mortensen (1993) found that the addition of 120 mg/day of CoQ 10 to conventional medical therapy for 8 weeks in patients with hypertension and coronary artery disease decreased systolic blood pressure by an average of 12 mm Hg and diastolic blood pressure by an average of 6 mm Hg as compared to a placebo containing B-complex vitamins. In patients with isolated systolic hypertension, the supplementation with 120 mg per day of coenzyme Q 10 and 300 IU/day of vitamin E for 12 weeks resulted in an average decrease of 17 mm Hg in systolic blood pressure compared with 300 IU/day of vitamin E alone.
Low blood levels of CoQ 10 have been found in people with hypertension but it is not clear if CoQ 10 deficiency is the cause of the high blood pressure. Research suggests that CoQ 10 causes small decreases in the blood pressure (Digiesi et al. 1990) . Greenberg and Frishman (1990) from the Sinai Hospital and Medical Centre in New York reported that the cardiovascular importance of CoQ 10 is being evidenced in clinical trials worldwide. In humans, a deficiency of CoQ 10 was found in 39% of patients with hypertension, compared to 6% of those with normal blood pressure. Providing these patients with 60 mg of CoQ 10 for eight weeks resulted in a 10% or greater decrease in blood pressure. Yamagami et al. (1986) in a double-blind study found that 20 hypertensive subjects with low serum CoQ 10 levels and receiving 100 mg of CoQ 10 per day for 12 weeks showed a significant reduction in systolic and diastolic blood pressures.
CoQ 10 and cancer. CoQ 10 may also have potential as an anticancerogenic and immune-stimulating agent. CoQ 10 in conjunction with conventional medical treatment and other antioxidant nutrients showed an increased survival rate and regression of cancer incidence. Numerous studies have noted the incidence of CoQ 10 deficiency in a variety of cancers including breast, lung, prostate, pancreatic, and colon cancer (Lockwood & Mosegaard 1994; Folkers & Osterborg 1997) . described a research in which thirty-two women with metastatic breast cancer received 90 mg of CoQ 10 daily, along with vitamins C and E, β-carotene, and essential fatty acids. In six cases, the tumor diminished. During the 18-month treatment period, none of the patients died and none showed signs of further distant metastases.
Two patients with metastatic breast cancer were treated with 390 mg/day of coenzyme Q 10 . One of the patients was a 44-year-old woman with numerous liver metastases. After taking CoQ 10 for 11 months, all of the liver metastases had disappeared and the patient was reported to be in excellent health. The other patient was a 49-year-old woman with breast cancer that had metastasised to the pleural cavity.
After six months of CoQ 10 therapy, all of the pleural fluid was gone and the patient was reported to be in excellent health (Folkers et al. 1993) .
CoQ 10 and periodontal disease. The gingival biopsies in patients having diseased periodontal tissue showed a deficiency of coenzyme Q 10 , in contrast to those with normal periodontal tissue who showed no deficiency (Littarru et al. 1971) . In some studies, CoQ 10 supplements caused faster healing and tissue repair (Inwamoto et al. 1981; Hanioka et al. 1994) . Additional studies are needed to evaluate the effectiveness of CoQ 10 when used together with the traditional therapy for periodontal disease.
CoQ 10 and bronchial asthma. CoQ 10 may be helpful in the treatment of respiratory diseases, especially asthma. Gazdík et al. (2002) described significantly decreased levels of CoQ 10 and α-tocopherol both in plasma and blood in patients with bronchial asthma, as compared with healthy subjects. Gvozdjáková et al. (2005) did a study which showed that patients with corticosteroid-dependent bronchial asthma had low plasma CoQ 10 concentrations which might contribute to their antioxidant imbalance and oxidative stress. The reduction in the dosage of corticosteroids required by the patients following the antioxidant supplementation means a lower incidence of adverse effects due to the drugs.
CoQ 10 and diabetes. The role of CoQ 10 in the energy formation also relates to how the body uses carbohydrates. Preliminary research suggests that a close relative of this nutrient lowered blood sugar levels in a group of people with diabetes. People with type 2 diabetes were found to have significantly lower blood levels of CoQ 10 as compared with healthy people (Miyake et al. 1999) .
The supplementation with 100 mg/day of CoQ 10 for 3 months neither improved glycemic control nor decreased insulin requirements in Type 1 diabetics compared to placebo. Similarly, 200 mg/day of CoQ 10 supplementation for 6 months did not improve glycemic control or serum lipid profiles in Type 2 diabetics. The authors of both studies concluded that CoQ 10 supplements could be used safely in diabetic patients (Eriksson et al. 1999; Henriksen et al. 1999) .
CoQ 10 and renal failure. CoQ 10 was studied in a small pilot study involving 21 patients with chronic renal failure. Researchers administered CoQ 10 to 11 of the subjects while 10 received a placebo capsule. After 4 weeks the number of patients on dialysis was significantly lower in the CoQ 10 group (36.2%) while 90.0% of patients in the placebo group were on dialysis at the end of the study (Singh et al. 2000) . Lippa et al. (1994) measured the levels of CoQ 10 in a group of 48 patients on chronic hemodialysis, in 15 uremic patients, and in a control group of healthy subjects. CoQ 10 levels were significantly lower (< 0.001) in both hemodialytic and uremic patients as compared with the normal group.
CoQ 10 and Parkinson disease. CoQ 10 showed some promise for slowing down the progression of Parkinson's disease in the early stage (Muller et al. 2003) . The research by Schultz showed that mitochondrial function is impaired in patients with Parkinson's disease and CoQ 10 levels are reduced in the mitochondria of Parkinsonian patients. Shults et al. (1999) in a national clinical trial including 80 patients with Parkinson's disease who did not require treatment for their disability, the patients who were given CoQ 10 supplements showed signs that the disease was progressing less rapidly than would have been expected. The greatest benefit was seen in everyday activities of the patients, such as feeding, dressing, bathing, and walking. CoQ 10 was safe and well tolerated at the dosages of up to 1200 mg/day (Shults et al. 2002) .
CoQ 10 and rheumatoid arthritis. By a study of Bauerová and Bezek (1999) and that of Jaswal et al. (2003) , oxidative stress is one of the primary factors involved in the pathogenetic changes during rheumatoid arthritis. Antirheumatic treatment affecting the level of CoQ 10 was found able to slow down the progression of this disease (Comstock et al. 1997; Knekt et al. 2000) .
Mitochondrial function in the heart and skeletal muscle and effectivity of supplementation with CoQ 10 was dependent on the severity of the induced adjuvant arthritis. The results with solubilised CoQ 10 (hydrosoluble form) indicate its cardioprotective effect in the experimental model of adjuvant arthritis. They are thus of potential significance in the treatment of patients with rheumatoid arthritis (Gvozdjáková et al. 2004; Kucharská et al. 2005; Bauerová et al. 2008) .
CONCLUSIONS
The exciting new findings by scientific researchers suggest that CoQ 10 is an important antioxidant readily used by the body and delaying various the progress of diseases under medical supervision.
CoQ 10 is very popular as a freely available dietary supplement, too. But only little has been published on its recommended daily intake and bioavailability. More researches are needed to examine the appropriate dose, effectiveness, and bioavailability of orally-administered and topically-administered coenzyme Q 10 . In our present experimental research study, we are working on the determination of the topical absorption of coenzyme Q 10 using in vitro OECD 428 method.
